Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | FNTA | P49354 | 3/20 | 0.61 |
| ▸ | FNTB | P49356 | 3/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | SQLE | Q14534 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Geranylacetol SCHEMBL30563824 | 0.98 | KMT2A (0.62) | KMT2AFNTAFNTBALOX15MAPT | |
| SCHEMBL14252442 | 0.88 | KMT2A (0.61) | KMT2AFNTAFNTBALOX15MAPT | |
| SCHEMBL14252496 | 0.88 | KMT2A (0.61) | KMT2AFNTAFNTBALOX15MAPT | |
| SCHEMBL3111482 | 0.86 | KMT2A (0.73) | KMT2AFNTAFNTBALOX15MAPT | |
| SCHEMBL112856 | 0.86 | KMT2A (0.73) | KMT2AFNTAFNTBALOX15MAPT | |
| SCHEMBL7934894 | 0.86 | KMT2A (0.73) | KMT2AFNTAFNTBALOX15MAPT | |
| SCHEMBL14236831 | 0.86 | KMT2A (0.73) | KMT2AFNTAFNTBALOX15MAPT | |
| SCHEMBL157509 | 0.86 | KMT2A (0.73) | KMT2AFNTAFNTBALOX15MAPT | |
| SCHEMBL7946216 | 0.86 | KMT2A (0.73) | KMT2AFNTAFNTBALOX15MAPT | |
| Farnesylacetol SCHEMBL157419 | 0.86 | KMT2A (0.73) | KMT2AFNTAFNTBALOX15MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153826-B2 | Process for production of (±)-3a,6,6,9a-Tetramethyldecahydronaphtho[2,1-b]Furan-2(1H)-one | KAO CORPORATION (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20090270639-A1 | PROCESS FOR PRODUCTION OF (±)-3A,6,6,9A- TETRAMETHYLDECAHYDRONAPHTHO[2,1-B]FURAN-2(1H)-ONE | KAO CORPORATION (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270639-A1 | PROCESS FOR PRODUCTION OF (±)-3A,6,6,9A- TETRAMETHYLDECAHYDRONAPHTHO[2,1-B]FURAN-2(1H)-ONE | COASY, FASN, CYP2C9 | KMT2A 3960/4885FNTA 1081/4885FNTB 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.